DDInter948 DDInter1956
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Zalcitabine {u} (Compound) resembles {v} (Compound) Emtricitabine
Zalcitabine {u} (Compound) resembles {v} (Compound) Decitabine
Zalcitabine {u} (Compound) binds {v} (Gene) DCK
Zalcitabine {u} (Compound) upregulates {v} (Gene) TRAPPC6A
Zalcitabine {u} (Compound) downregulates {v} (Gene) TUBB6
Zalcitabine {u} (Compound) causes {v} (Side Effect) Pollakiuria
Zalcitabine (Compound) resembles Emtricitabine (Compound)
Zalcitabine (Compound) resembles Decitabine (Compound)
Zalcitabine (Compound) binds DCK (Gene)
Zalcitabine (Compound) upregulates TRAPPC6A (Gene)
Zalcitabine (Compound) downregulates TUBB6 (Gene)
Zalcitabine (Compound) causes Pollakiuria (Side Effect)